AI And The ‘Black Box’ Problem: US FDA Is More Comfortable Than Some May Think

A recurring question about using artificial intelligence in drug development is whether the US Food and Drug Administration can accept a model that operates as a black box, meaning that developers cannot explain exactly how the model does what it does.